FDA Releases Draft Guidance for Psychedelic Clinical Trials.

The FDA has issued its first draft guidance for researchers investigating the use of psychedelic drugs for potential treatment of medical conditions, including psychiatric or substance use disorders. The guidance highlights fundamental considerations for designing clinical trials for psychedelic drugs, including safety measures to prevent misuse throughout clinical development. The FDA is encouraging the public to provide comments on the draft guidance within 60 days.